Botanical Solution, Inc. Amplifies Vaccine Adjuvant Production with a Fresh $7 Million Investment

0 Shares
0
0
0
0
0
0
0

Botanical Solution Inc. (BSI), a global trailblazer in the production of sustainable Advanced Botanical Materials, announces the addition of $7 million to its coffers, taking their Series A funding to an impressive total of over $13 million.

This influx of capital comes after BSI’s recent partnership with Croda, aiming to fast-track the production of an eco-friendly and high-quality version of the vaccine adjuvant QS-21, maintaining standards compliant with Good Manufacturing Practices (GMP). The company’s initiatives and collaborations with top pharmaceutical companies underscore that their innovative QS-21 is as effective and immunologically potent as its traditional version, derived from ancient soapbark trees indigenous to Chile.

This timely financial boost is set to solidify BSI’s foundation in constructing a sustainable supply chain for QS-21, often referred to as the ‘gold standard’ in vaccine adjuvants. Moreover, it will fuel BSI’s agricultural expansion plans, which feature the launch of their premium product, Quillibrium®, in regions including Mexico, Brazil, the US, and the EU. BSI’s thriving collaboration with Syngenta since 2019 has resulted in a commendable 50% year-on-year increase in the adoption rate among growers in Chile and Peru, with an impressive expanse of over 100,000 acres benefitting from their product.

Otter Capital helmed this financing round, with significant participation from Latin American investors like Boldo SpA and Quebec LP. Both entities, overseen by the Casanueva and Saval family offices, bring their keen interest in tech and pharmaceutical ventures to the table.

“BSI is poised to commence the delivery of GMP-compliant materials pivotal for crafting human vaccines within this year,” shared the company. CEO Gaston Salinas expressed his gratitude, stating, “The unwavering support from our dedicated investors fortifies our mission. Our advanced technologies and sustainable products are geared towards not only enhancing the supply chain of QS-21 but also confronting the predominant challenges in modern agricultural disease control.”

About Botanical Solution, Inc.
A Delaware Corporation, BSI takes pride in its unique platform dedicated to the eco-friendly and consistent production of Advanced Botanical Materials. Their pioneering product, ABM-01, sourced from the Quillaja saponaria plant, is the cornerstone of two acclaimed products: the biopesticide Quillibrium® and the vaccine adjuvant QS-21. The latter finds its use in groundbreaking vaccines targeting Shingles, RSV, and Malaria. Their innovative endeavors have garnered them significant accolades, such as the “2023 Best Process Innovation Award” and the “2022 Product of the Year Award.”

For more insights, visit: BSI Website.

Leave a Reply

Your email address will not be published. Required fields are marked *